{
    "Title": "Preclinical toxicity and pharmacokinetics of a new orally bioavailable flubendazole formulation and the impact for clinical trials and risk/benefit to patients",
    "URL": "https://doi.org/10.1371/journal.pntd.0007026",
    "Published": "January 16, 2019",
    "Subject_Areas": [
        "Dogs",
        "Toxicity",
        "Oral administration",
        "Blood plasma",
        "Micronuclei",
        "Red blood cells",
        "Metabolites",
        "Atrophy"
    ],
    "Authors": {
        "Sophie Lachau-Durand": [
            "Drug Metabolism and Pharmacokinetics, Janssen Research & Development, A Division of Janssen Pharmaceutica NV, Beerse, Belgium"
        ],
        "Lieve Lammens": [
            "Nonclinical Safety, Janssen Research & Development, A Division of Janssen Pharmaceutica NV, Beerse, Belgium"
        ],
        "Bas-jan van der Leede": [
            "Nonclinical Safety, Janssen Research & Development, A Division of Janssen Pharmaceutica NV, Beerse, Belgium"
        ],
        "Jacky Van Gompel": [
            "Nonclinical Safety, Janssen Research & Development, A Division of Janssen Pharmaceutica NV, Beerse, Belgium"
        ],
        "Graham Bailey": [
            "Nonclinical Safety, Janssen Research & Development, A Division of Janssen Pharmaceutica NV, Beerse, Belgium"
        ],
        "Marc Engelen": [
            "Project Management Office, Janssen Research & Development, A Division of Janssen Pharmaceutica NV, Beerse, Belgium"
        ],
        "Ann Lampo": [
            "Nonclinical Safety, Janssen Research & Development, A Division of Janssen Pharmaceutica NV, Beerse, Belgium"
        ]
    }
}